Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

HF Bernard; A (Astrid) Capello; P.M. van Hagen; Wout Breeman; A Srinivasan; M Schmidt; JL Erion; A Gameren; Eric Krenning; Marion Jong

doi:10.1089/108497804323071940

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

HF Bernard
, A (Astrid) Capello
, P.M. van Hagen
, Wout Breeman
, A Srinivasan
, M Schmidt
, JL Erion
, A Gameren
, Eric Krenning
, Marion Jong

Research output: Contribution to journal › Article › Academic › peer-review

39 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	173-180
Number of pages	8
Journal	Cancer Biotherapy & Radiopharmaceuticals
Volume	19
Issue number	2
DOIs	https://doi.org/10.1089/108497804323071940
Publication status	Published - 2004

Research programs

EMC MM-01-40-01
EMC MM-02-72-01

Access to Document

10.1089/108497804323071940

http://hdl.handle.net/1765/61484

Cite this

@article{fb3228a9479f409998e854888f7d2e94,

title = "Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.",

author = "HF Bernard and Capello, \{A (Astrid)\} and \{van Hagen\}, P.M. and Wout Breeman and A Srinivasan and M Schmidt and JL Erion and A Gameren and Eric Krenning and Marion Jong",

year = "2004",

doi = "10.1089/108497804323071940",

language = "Undefined/Unknown",

volume = "19",

pages = "173--180",

journal = "Cancer Biotherapy \& Radiopharmaceuticals",

issn = "1084-9785",

publisher = "Mary Ann Liebert Inc.",

number = "2",

}

TY - JOUR

T1 - Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

AU - Bernard, HF

AU - Capello, A (Astrid)

AU - van Hagen, P.M.

AU - Breeman, Wout

AU - Srinivasan, A

AU - Schmidt, M

AU - Erion, JL

AU - Gameren, A

AU - Krenning, Eric

AU - Jong, Marion

PY - 2004

Y1 - 2004

U2 - 10.1089/108497804323071940

DO - 10.1089/108497804323071940

M3 - Article

C2 - 15186597

SN - 1084-9785

VL - 19

SP - 173

EP - 180

JO - Cancer Biotherapy & Radiopharmaceuticals

JF - Cancer Biotherapy & Radiopharmaceuticals

IS - 2

ER -